Matthew L. Trerotola
Matthew L. Trerotola's purchase track record
Matthew L. Trerotola has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 11/3/2022 | ATR | $300K | +24.3% | +26.3% | +9.2% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
Solstice Settles Lawsuit; Mizuho Cuts Target to $65. Solstice Advanced Materials announced a settlement with plaintiffs, stating it does not expect a material impact on business operations or financial performance. In related analyst activity, Mizuho lowered its price target to $65 while maintaining a Neutral rating, whereas RBC Capital reiterated an Outperform rating with an $82 target. The company is also scheduled to report third-quarter results on November 4, 2026.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Enovis Gathers Fresh Attention After Reaffirming 2026 Guidance. Enovis has attracted new interest as analysts discuss its 2026 outlook. A recent review lowered the price target to $34 while maintaining a positive stance. The stock is trading near the top of its 52‑week range, and recent signals show a breakout and positive RSI divergence. These developments may influence how investors view the company’s valuation.
Transaction History
| ATR | ▲ Buy | Grant | 151 | $0 | 7/16/2026 | View on chart |
| SOLS | ▲ Buy | Option Exercise | 1,785 | — | 5/22/2026 | View on chart |
| ATR | ▲ Buy | Grant | 1,326 | $0 | 5/6/2026 | View on chart |
| ATR | ▲ Buy | Grant | 1,069 | $0 | 5/7/2025 | View on chart |
| ENOV | ▲ Buy | Grant | 94,135 | $0 | 3/7/2025 | View on chart |
| ENOV | ▼ Sell | Tax Withholding | 9,879 | $362K | 3/4/2025 | View on chart |
| ENOV | ▼ Sell | Tax Withholding | 4,102 | $159K | 2/28/2025 | View on chart |
| ENOV | ▲ Buy | Grant | 47,394 | $0 | 2/17/2025 | View on chart |
| ENOV | ▼ Sell | Tax Withholding | 24,108 | $1.1M | 2/17/2025 | View on chart |
| ATR | ▲ Buy | Grant | 1,113 | $0 | 5/1/2024 | View on chart |
| ENOV | ▼ Sell | Tax Withholding | 6,157 | $381K | 3/6/2024 | View on chart |
| ENOV | ▲ Buy | Grant | 64,484 | $0 | 3/4/2024 | View on chart |
| ENOV | ▼ Sell | Tax Withholding | 4,319 | $258K | 3/1/2024 | View on chart |
| ENOV | ▼ Sell | Tax Withholding | 23,213 | $1.5M | 2/23/2024 | View on chart |
| ENOV | ▲ Buy | Grant | 45,635 | $0 | 2/22/2024 | View on chart |
| ENOV | ▼ Sell | Tax Withholding | 3,444 | $204K | 2/20/2024 | View on chart |
| ATR | ▲ Buy | Grant | 1,266 | $0 | 5/3/2023 | View on chart |
| ENOV | ▼ Sell | Open Market | 6,743 | $389K | 3/6/2023 | View on chart |
| ENOV | ▲ Buy | Grant | 28,221 | $0 | 2/28/2023 | View on chart |
| ENOV | ▲ Buy | Grant | 32,283 | $0 | 2/27/2023 | View on chart |
| ENOV | ▼ Sell | Open Market | 18,917 | $1.1M | 2/27/2023 | View on chart |
| ENOV | ▼ Sell | Open Market | 3,945 | $215K | 2/23/2023 | View on chart |
| ENOV | ▼ Sell | Open Market | 3,780 | $235K | 2/21/2023 | View on chart |
| ATR | ▲ Buy | Open Market | 3,170 | $300K | 11/3/2022 | View on chart |
| ATR | ▲ Buy | Grant | 1,208 | $0 | 10/13/2022 | View on chart |
| ENOV | ▼ Sell | Open Market | 12,002 | $467K | 3/7/2022 | View on chart |
| ENOV | ▼ Sell | Open Market | 100 | $4K | 2/28/2022 | View on chart |
| ENOV | ▼ Sell | Open Market | 6,534 | $270K | 2/28/2022 | View on chart |
| ENOV | ▼ Sell | Open Market | 57,497 | $2.3M | 2/28/2022 | View on chart |
| ENOV | ▼ Sell | Open Market | 34,937 | $1.4M | 2/28/2022 | View on chart |
| ENOV | ▲ Buy | Grant | 185,067 | $0 | 2/25/2022 | View on chart |
| ENOV | ▼ Sell | Open Market | 6,465 | $270K | 2/23/2022 | View on chart |
| ENOV | ▲ Buy | Grant | 40,284 | $0 | 2/17/2022 | View on chart |
| ENOV | ▼ Sell | Open Market | 110 | $6K | 11/8/2021 | View on chart |
| ENOV | ▲ Buy | Option Exercise | 50,000 | $2.0M | 11/8/2021 | View on chart |
| ENOV | ▼ Sell | Open Market | 49,890 | $2.6M | 11/8/2021 | View on chart |
| ENOV | ▼ Sell | Open Market | 12,801 | $651K | 10/15/2021 | View on chart |
| ENOV | ▼ Sell | Open Market | 37,199 | $1.9M | 10/15/2021 | View on chart |
| ENOV | ▲ Buy | Option Exercise | 50,000 | $2.0M | 10/15/2021 | View on chart |
| ENOV | ▼ Sell | Open Market | 59,563 | $2.8M | 9/13/2021 | View on chart |
| ENOV | ▲ Buy | Option Exercise | 59,563 | $1.4M | 9/13/2021 | View on chart |
| ENOV | ▲ Buy | Option Exercise | 150,000 | $3.6M | 8/16/2021 | View on chart |
| ENOV | ▼ Sell | Open Market | 70,706 | $3.5M | 8/16/2021 | View on chart |
| ENOV | ▼ Sell | Open Market | 5,290 | $262K | 8/16/2021 | View on chart |
| ENOV | ▼ Sell | Open Market | 4,294 | $213K | 8/16/2021 | View on chart |
| ENOV | ▼ Sell | Open Market | 1,446 | $72K | 8/16/2021 | View on chart |
| ENOV | ▼ Sell | Open Market | 69,710 | $3.4M | 8/16/2021 | View on chart |
| ENOV | ▲ Buy | Option Exercise | 1,446 | $57K | 8/16/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
AptarGroup Secures CE Marking for LuerVax as UBS Starts Coverage
AptarGroup announced that its LuerVax product and accompanying spray divider have received CE marking, a regulatory step that supports vaccine developers. Separately, UBS initiated coverage on the stock with a neutral rating and a price target of $135. The company's average analyst target remains $162.00, with a range extending to $220.00.
AptarGroup Secures CE Marking for LuerVax as UBS Starts Coverage. AptarGroup announced that its LuerVax product and accompanying spray divider have received CE marking, a regulatory step that supports vaccine developers. Separately, UBS initiated coverage on the stock with a neutral rating and a price target of $135. The company's average analyst target remains $162.00, with a range extending to $220.00.